Interestingly, and of importance for the potential use of this compound against poor-prognosis ALL, Gontarewicz et al, using Bcr/Abl constructs transfected into the BaF3 cell line, showed that PHA-739358 is also effective against imatinib-resistant Bcr/Abl mutants including the T315I [24]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.